Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switched Memory B-cells for IGRT Discontinuation in SAD
NCT05612607Phase 4Not yet recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Biologic
01
Overview
Phase 4, open-label, single-arm trial in secondary antibody deficiency, sponsored by Ottawa Hospital Research Institute. Primary endpoints: IGRT discontinuation success rate and IGRT discontinuation rate. Planned start Nov 2022; status: not yet recruiting.
02
Conditions
secondary antibody deficiency
Beyond the preview
Go deeper on NCT05612607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05612607.